Camilla Christina Pedersen

Camilla Christina Pedersen

Auto-generated profile, based on publicly available information

Camilla Christina Pedersen

Centre for Movement Disorders Stavanger University Hospital Stavanger Norway

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2024 in npj Parkinson's Disease
Verified
Journal Article
Open access
PDF file
CPCamilla Christina Pedersen
Camilla Christina Pedersen
AUAnastasia Ushakova
Anastasia Ushakova
GAGuido Alves
Guido Alves
OTOle-Bjørn Tysnes
Ole-Bjørn Tysnes
KBKaj Blennow
Kaj Blennow
Johannes LangeJohannes Lange
Johannes Lange
Neurofilament light chain (NFL) is elevated in neurodegenerative diseases, including Parkinson’s disease (PD). This study aimed to investigate serum NFL in newly diagnosed PD and its association with cognitive and motor decline over 10 years. Serum NFL levels were measured in PD patients and controls from the ParkWest study at diagnosis (baseline) and after 3 and 5 years. Mixed-effects regression analyzed changes in NFL and the association with annual changes in MMSE and UPDRS-III scores over 10 years. PD patients had elevated serum NFL at all visits and a faster annual increase over 5 years compared to controls (0.09 pg/mL per year; p = 0.029). Higher baseline NFL predicted faster cognitive decline β −0.77 transformed MMSE; p = 0.010), and a 40% NFL increase predicted future motor decline (β 0.28 UPDRS-III; p = 0.004). Elevated serum NFL in early PD is linked to faster cognitive and motor impairment, suggesting its prognostic value in PD biomarker panels.

2 June 2025 in European Journal of Neurology
Verified
Journal Article
Open access
CPCamilla Christina Pedersen
Camilla Christina Pedersen
GAGuido Alves
Guido Alves
OTOle‐Bjørn Tysnes
Ole‐Bjørn Tysnes
JMJodi Maple‐Grødem
Jodi Maple‐Grødem
Johannes LangeJohannes Lange
Johannes Lange
Background: Alpha‐synuclein (α‐syn), phosphorylated at serine 129 (pS129‐α‐syn), is a potential biomarker for Parkinson's disease (PD) because it is the predominant α‐syn species found in Lewy bodies.Methods: We developed an in‐house SIMOA assay, using commercially available components, to quantify pS129‐α‐syn in CSF. The clinical utility of the assay was tested in CSF from 120 patients with PD from the Norwegian ParkWest longitudinal study and 29 normal controls. Prior measurements of CSF total (t)‐α‐syn and the pS129‐α‐syn/t‐α‐syn ratio were included for comparison.Results: The lower limit of quantification of the in‐house assay used to analyze CSF samples from participants was 0.57 pg/mL, which was well below the observed concentrations of endogenous pS129‐α‐syn in CSF. Median CSF pS129‐α‐syn levels were slightly lower in PD patients compared to controls (5.7 pg/mL vs. 6.5 pg/mL), but the difference was not significant in the unadjusted (p = 0.404) or adjusted analyses (p = 0.270). There was no difference in the pS129‐α‐syn/t‐α‐syn ratio between patients and controls. Using linear mixed‐effects models, we found no association between baseline pS129‐α‐syn or the pS129‐α‐syn/t‐α‐syn ratio and motor or cognitive decline over a 10‐year period.Conclusion: We developed and applied an in‐house SIMOA that reliably quantifies pS129‐α‐syn in CSF samples. This study does not indicate a role for CSF pS129‐α‐syn or the pS129‐α‐syn/t‐α‐syn ratio as clinically useful diagnostic or prognostic biomarkers in PD.